Vice President Naidu, Health News, ET HealthWorld
Noting that India has since ancient times had a very systematic, scientific and rational approach to treating diseases, he said that the country has now become the third largest drug manufacturer in the world.
Addressing the 70th Indian Pharmaceutical Congress, held at Amity University, Noida, the vice president said that at present, more than 80 percent of antiretroviral drugs used worldwide to fight AIDS are supplied by Indian pharmaceutical companies.
“Due to the ability of Indian pharmaceutical companies to produce drugs at economical prices, the cost of treating HIV / AIDS has increased from $ 12,000 to $ 400 per year – a dramatic contribution to global health care. India also has a vast pool of talented scientists and engineers who have the potential to take the industry to greater heights, ”he said, according to an official statement.
The Center has taken a number of initiatives to create an ecosystem that fosters manufacturing and has identified a few key areas, with pharmaceuticals being one of those due to the immense reach of technology, innovation and research, he said.
Naidu said India already has the second highest number of US FDA approved facilities and labor costs in India are significantly lower than other manufacturing centers and the 2017-2018 Union budget shows a 23% increase in health spending which is likely to give new impetus to the pharmaceutical sector.
“The government has proposed changes to the rules on drugs and cosmetics to ensure the availability of generic drugs at reasonable prices and to promote the use of generic drugs. It also introduced a series of tax incentives to promote domestic manufacturing, including the reduction of reverse duties. structure and basic tariffs, ”he said.
Noting that drug patenting is important to catalyze the growth of the pharmaceutical industry, the vice president said India has always taken “a bold and exemplary position” against “blind patent protection that benefits the world’s pharmaceutical giants” .
“This uncompromising position was demonstrated by the granting of a compulsory license in 2012 to an Indian manufacturer to produce a cancer drug, the patent of which was held by the German company Bayer. Bayer’s price had made the drug unaffordable for poor cancer patients in India. , in Africa and elsewhere, “he said.
The Supreme Court of India also upheld the 2006 ruling by the Indian Patent Office which denied a patent for a simple incremental innovation to a Swiss pharmaceutical major. The verdict rejecting patent protection sparked an international outcry, Naidu recalled.
“Providing essential drugs and medicines at cost-effective prices is the main objective of the Pharmaceuticals Department of the Ministry of Chemicals and Fertilizers,” Naidu said.
“As part of the national pricing policy for pharmaceutical products, as of December 15, 2016, the ceiling prices of 853 formulations are controlled. The setting of drug price ceilings has resulted in a total savings of $ 392 million since May 2014, ”he said.
Naidu said that India has successfully retained its “pioneering heritage” in the field of pharmacology and today enjoys the exalted position of being the “pharmacy of the world”.
“The pharmaceutical industry has shown robust double-digit growth in recent years. The industry was worth $ 36.7 billion in 2017 and is expected to reach $ 55 billion by 2020 … India is now among the top five emerging markets in the world, ”Naidu said.
He said India is the world’s largest supplier of generic drugs, accounting for 20% of global exports by volume, with their exports increasing at a “very impressive” rate of around 24% per year over the past four years. last years.
“In 2012-13, India’s pharmaceutical exports amounted to $ 14.7 billion. More than half went to Western markets which have strict regulations and strong accountability mechanisms. It is an eloquent testament to the competence of the Indian pharmaceutical sector in terms of quality. and prices, ”said the vice president.
He said that the country has the desire and the capacity to absorb new technologies in manufacturing and that “Make in India” is one of the key programs launched by the government to stimulate the economy and that the goal is to transform India into a global manufacturing center.
Naidu said that “Pharma Jan Samadhan”, a system for resolving customer complaints has been launched and that a mobile application – “Pharma Sahi Daam” which provides real-time information to consumers on the prices of scheduled / non-scheduled drugs. programmed has also been introduced.
In addition, quality medicines at affordable prices are now available to the poor and disadvantaged through “Pradhan Mantri Bhartiya Jan aushadhi Kendras,” he said.
“There are over 700 drugs; more than 150 surgical products and consumables are available at affordable prices for all in more than 4000 “Jan Aushadi Kedras” across the country.
“In a very proactive approach, the government is setting up an electronic platform to regulate the profusion of online pharmacies that are arriving, under a new policy, to stop any misuse due to easy availability” , added Naidu.